Viron's pipeline of drug candidates meet a number of currently unmet medical needs that physicians and researchers are seeking to address. Viron's compounds represent a completely novel class of protein therapeutics that can be used in the treatment of a wide range of inflammatory and autoimmune diseases and have unique advantages over conventional drug therapeutics. Viron has three core programs along with several early stage programs as follows:
VT-111a/b (monocyte/macrophage inhibitor)
There are currently no therapies specifically targeting monocyte/macrophage migration, and procedurally-driven damage following cardiac intervention and organ transplant rejection continue to be serious problems. VT-111 reduces monocyte/macrophage migration into regions of vascular damage and it demonstrated a reduction in major adverse cardiac events (MACE) and cardiac enzyme markers of myocardial tissue death in a recent Phase 2 study.
VT-346 (TNF-alpha binding protein)
Currently marketed anti-TNFs do not drive TNF levels low enough for maximal clinical benefit. Up to 50% of patients do not respond to available treatments. VT-346 demonstrates 10-100 times stronger binding affinity for TNF-α compared to currently available anti-TNFs, which may result in more effective reduction of TNF trough levels. VT-346's novel binding mechanism allows it to successfully target patients that do not respond to marketed anti-TNFs.
VT-384 (IL-18 binding protein)
The importance of IL-18 is growing as its pivotal role in inflammatory responses is further understood. The complicated antibody patent landscape for IL-18 has made it very difficult for companies to establish programs targeting this cytokine. VT-384 is not an antibody, and is therefore a uniquely positioned therapeutic target of increasing interest in the pharmaceutical industry. Viron has developed two versions of the molecule (18 kDa and 80 kDa), which opens up the possibility for use in different indications.
VT-310 (IL-10 homolog)
VT-310 is a homolog of human IL-10 and is closely related to IL-24. Early activity assay studies suggest that VT-310 is able to induce STAT3 phosphorylation to a much greater extent than human IL-10.
VT-214 (chemokine binding protein)
Currently available chemokine pathway inhibitors are generally limited to only one subset of chemokines (ie. C or CC or CXC). In contrast, VT-214 has demonstrated binding to the C-terminal heparin binding domain that is found in all three classes (C, CC and CXC) of human chemokines.
VT-362 is a viral homolog of the cellular protein CD30, and binds to CD153 with high affinity. VT-362 prevents T-cell activation in vitro and prevents the induction of a type 1 T-cell response in vivo, which is associated with the induction of proinflammatory cytokines such as interferon-gamma and IL-12.